Abstract
Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A. baumannii are on the rise and are slowly becoming a routine phenotype for this organism. This review focuses on infection control strategies for identification and control of A. baumannii, as well the available therapeutic options.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acinetobacter Infections / drug therapy*
-
Acinetobacter Infections / epidemiology*
-
Acinetobacter Infections / microbiology
-
Acinetobacter baumannii / classification
-
Acinetobacter baumannii / drug effects
-
Acinetobacter baumannii / genetics*
-
Aminoglycosides / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Carbapenems / therapeutic use
-
Colistin / therapeutic use
-
Disease Management
-
Disease Outbreaks*
-
Epidemiological Monitoring
-
Humans
-
Minocycline / analogs & derivatives
-
Minocycline / therapeutic use
-
Tigecycline
-
beta-Lactam Resistance / drug effects
-
beta-Lactam Resistance / genetics*
-
beta-Lactamases / classification
-
beta-Lactamases / genetics
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Carbapenems
-
Tigecycline
-
beta-Lactamases
-
Minocycline
-
Colistin